Ethylmalonic encephalopathy is a rare autosomal recessive mitochondrial disorder caused by pathogenic biallelic variants in the ETHE1 gene. The phenotype of this disease has been attributed to deficiency in the mitochondrial sulfur dioxygenase leading to many downstream effects. Ethylmalonic encephalopathy classically presents with developmental regression, petechiae, acrocyanosis, and chronic diarrhea. The neurologic phenotype includes hypotonia, spastic diplegia, ataxia, and developmental delay. As more patients with this condition are described, the neurologic phenotype continues to expand. Although strokelike episodes or metabolic strokes have been studied in other mitochondrial disorders, they have not been thoroughly reported in this disorder. Herein, we describe 3 patients with ethylmalonic encephalopathy who presented clinically with strokelike episodes and strokelike abnormalities on brain magnetic resonance imaging in the setting of acute illness, and the long-term sequelae with evolution into cystic changes in one of these subjects.
AlfadhelMBenmeakelMHossainMA, et al.Thirteen year retrospective review of the spectrum of inborn errors of metabolism presenting in a tertiary center in Saudi Arabia. Orphanet J Rare Dis. 2016;11:126.
2.
BurlinaABDionisi-ViciCBennettMJ, et al.A new syndrome with ethylmalonic aciduria and normal fatty acid oxidation in fibroblasts. J Pediatr. 1994;124:79–86.
3.
GrossoSMostardiniRFarnetaniMA, et al.Ethylmalonic encephalopathy: further clinical and neuroradiological characterization. J Neurol. 2002;249:1446–1450.
4.
TirantiVViscomiCHildebrandtT, et al.Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. Nat Med. 2009;15:200–205.
5.
Di MeoIFagiolariGPrelleAViscomiCZevianiMTirantiV. Chronic exposure to sulfide causes accelerated degradation of cytochrome c oxidase in ethylmalonic encephalopathy. Antioxid Redox Signal. 2011;15:353–362.
6.
Di MeoILampertiCTirantiV. Mitochondrial diseases caused by toxic compound accumulation: from etiopathology to therapeutic approaches. EMBO Mol Med. 2015;7:1257–1266.
7.
GiordanoCViscomiCOrlandiM, et al.Morphologic evidence of diffuse vascular damage in human and in the experimental model of ethylmalonic encephalopathy. J Inherit Metab Dis. 2012;35:451–458.
8.
KitzlerTMGuptaIROstermanB, et al.Acute and chronic management in an atypical case of ethylmalonic encephalopathy. JIMD Rep. 2019;45:57–63.
9.
PigeonNCampeauPMCyrDLemieuxBClarkeJT. Clinical heterogeneity in ethylmalonic encephalopathy. J Child Neurol. 2009;24:991–996.
10.
McGowanKANyhanWLBarshopBA, et al.The role of methionine in ethylmalonic encephalopathy with petechiae. Arch Neurol. 2004;61:570–574.
11.
PapettiLGaroneGSchettiniL, et al.Severe early onset ethylmalonic encephalopathy with West syndrome. Metab Brain Dis. 2015;30:1537–1545.
12.
GovindarajPParayil SankaranBNagappaM, et al.Child neurology: ethylmalonic encephalopathy. Neurology. 2020;94:e1336–e1339.
13.
TavasoliARRostamiPAshrafiMRKarimzadehP. Neurological and vascular manifestations of ethylmalonic encephalopathy. Iran J Child Neurol. 2017;11:57–60.
14.
PeakeRWARodanLH. Ethylmalonic aciduria in an infant with neurological and skin presentation. Clin Chem. 2017;63:1771–1773.
15.
KilicMDedeogluOGocmenRKesiciSYukselD. Successful treatment of a patient with ethylmalonic encephalopathy by intravenous N-acetylcysteine. Metab Brain Dis. 2017;32:293–296.
16.
BhatMDPrasadCTiwariSChandraSRChristopherR. Diffusion restriction in ethylmalonic encephalopathy—an imaging evidence of the pathophysiology of the disease. Brain Dev. 2016;38:768–771.
17.
Bijarnia-MahaySGuptaDShigematsuYYamaguchiSSaxenaRVermaIC. Ethylmalonic encephalopathy in an Indian boy. Indian Pediatr. 2016;53:914–916.
18.
YisUPolatIKarakayaPAyanogluMHizAS. Importance of acrocyanosis in delayed walking. J Pediatr Neurosci. 2015;10:80–81.
19.
CavusogluDHismiBODundarNO, et al.An unusual cause of cavitating leukoencephalopathy: ethylmalonic encephalopathy. Acta Neurol Belg. 2018;118:309–312.
20.
Dionisi-ViciCDiodatoDTorreG, et al.Liver transplant in ethylmalonic encephalopathy: a new treatment for an otherwise fatal disease. Brain. 2016;139:1045–1051.
21.
OzandPTRashedMMillingtonDS, et al.Ethylmalonic aciduria: an organic acidemia with CNS involvement and vasculopathy. Brain Dev. 1994;16(suppl):12–22.
22.
DebrayFGMorinCJanvierA, et al.LRPPRC mutations cause a phenotypically distinct form of Leigh syndrome with cytochrome c oxidase deficiency. J Med Genet. 2011;48:183–189.
23.
FuruyaHSugimuraTYamadaTHayashiKKobayashiT. A case of incomplete Kearns-Sayre syndrome with a stroke like episode [in Japanese]. Rinsho Shinkeigaku. 1997;37:680–684.
24.
LamCWLawCYSiuWK, et al.Novel POLG mutation in a patient with sensory ataxia, neuropathy, ophthalmoparesis and stroke. Clin Chim Acta. 2015;448:211–214.
25.
TzoulisCHenriksenEMileticHBindoffLA. No evidence of ischemia in stroke-like lesions of mitochondrial POLG encephalopathy. Mitochondrion. 2017;32:10–15.
26.
WeiYCuiLPengB. Mitochondrial DNA mutations in late-onset Leigh syndrome. J Neurol. 2018;265:2388–2395.
27.
FordLKennedyADGoodmanKD, et al.Precision of a clinical metabolomics profiling platform for use in the identification of inborn errors of metabolism. J Appl Lab Med. 2020;5:342–356.
28.
TamAAlDhaheriNSMysoreK, et al.Improved clinical outcome following liver transplant in patients with ethylmalonic encephalopathy. Am J Med Genet A. 2019;179:1015–1019.
29.
RodanLHMishraNYauIAndradeASiriwardenaKTeinI. Expanding the spectrum of methylmalonic acid-induced pallidal stroke: first reported case of metabolic globus pallidus stroke in transcobalamin II deficiency. JIMD Rep. 2013;11:7–11.
30.
RossiABiancheriRBrunoC, et al.Leigh syndrome with COX deficiency and SURF1 gene mutations: MR imaging findings. AJNR Am J Neuroradiol. 2003;24:1188–1191.
BhatiaKDKrishnanPKortmanHKlostranecJKringsT. Acute cortical lesions in MELAS syndrome: anatomic distribution, symmetry, and evolution. AJNR Am J Neuroradiol. 2020;41:167–173.
33.
FinstererJ. Mitochondrial metabolic stroke: phenotype and genetics of stroke-like episodes. J Neurol Sci. 2019;400:135–141.
34.
CheldiARonchiDBordoniA, et al.POLG1 mutations and stroke like episodes: a distinct clinical entity rather than an atypical MELAS syndrome. BMC Neurol. 2013;13:8.
35.
TzoulisCBindoffLA. Serial diffusion imaging in a case of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. Stroke. 2009;40:e15–e17.
36.
IizukaTSakaiFSuzukiN, et al.Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome. Neurology. 2002;59:816–824.
37.
OhshitaTOkaMImonY, et al.Serial diffusion-weighted imaging in MELAS. Neuroradiology. 2000;42:651–656.
38.
WhitemanMLiLKostetskiI, et al.Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide. Biochem Biophys Res Commun. 2006;343:303–310.
39.
YangGWuLJiangB, et al.H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science. 2008;322:587–590.
40.
RakMBenitPChretienD, et al.Mitochondrial cytochrome c oxidase deficiency. Clin Sci (Lond). 2016;130:393–407.
41.
LampertiCDiodatoDLamanteaE, et al.MELAS-like encephalomyopathy caused by a new pathogenic mutation in the mitochondrial DNA encoded cytochrome c oxidase subunit I. Neuromuscul Disord. 2012;22:990–994.
42.
RitterLKleemannDHickmannFH, et al.Disturbance of energy and redox homeostasis and reduction of Na+, K+-ATPase activity provoked by in vivo intracerebral administration of ethylmalonic acid to young rats. Biochim Biophys Acta. 2015;1852:759–767.
Di MeoIAuricchioALampertiCBurlinaAViscomiCZevianiM. Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy. EMBO Mol Med. 2012;4:1008–1014.
